Vismodegib

Chemical formula: C₁₉H₁₄Cl₂N₂O₃S  Molecular mass: 421.297 g/mol  PubChem compound: 24776445

Active ingredient description

Vismodegib is an orally available small-molecule inhibitor of the Hedgehog pathway. Hedgehog pathway signalling through the Smoothened transmembrane protein (SMO) leads to the activation and nuclear localisation of Glioma-Associated Oncogene (GLI) transcription factors and induction of Hedgehog target genes. Vismodegib binds to and inhibits the SMO protein thereby blocking Hedgehog signal transduction.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L01XJ01 L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XJ Hedgehog pathway inhibitors
Discover more medicines within L01XJ01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
ERIVEDGE Hard capsule European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 879085-55-9
DrugBank Drug: DB08828
KEGG Drug: D09992
PubChem Compound: 24776445
RxNorm Ingredient: 1242987
SNOMED-CT Concept: 703812008
Vismodegib (substance)
UNII Identifier: 25X868M3DS
VISMODEGIB

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.